Richard E. Cutler - Concepedia

Author

Richard E. Cutler

Also Known As

Cutler Jr., Richard E., R Cutler, R. Cutler, R. E. Cutler, R.E. Cutler, Richard Cutler, Richard E Cutler, Richard E. CUTLER, Richard E. Cutler, Richard E. Cutler Jr

Publications

Citations

H-Index

Concepts

All Affiliations

Puma Biotechnology (United States)Memorial Sloan Kettering Cancer Center Virginia Commonwealth University Northwestern University The University of Texas MD Anderson Cancer Center

About

Richard E. Cutler is an author at Puma Biotechnology (United States) specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1.3K
2	Natural Sciences	2	2	37
3	Public Health	2	2	44
4	Biochemistry	2	2	37
5	Health Sciences	1	1	33

Richard E. Cutler

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
HER kinase inhibition in patients with HER2- and HER3-mutant cancers David M. Hyman, Sarina A. Piha‐Paul, Helen Won, Nature Tumor BiologyOncologyMedicineReceptor Tyrosine KinasePathology	2018	752
Autoregulation of the Raf-1 serine/threonine kinase Richard E. Cutler, Robert M. Stephens, Misty Saracino, Proceedings of the National Academy of Sciences Signal TransductionDevelopmental BiologySignaling PathwayReceptor Tyrosine KinaseAutophagy	1998	198
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation Torsten Trowe, Sotiria Boukouvala, Keith Calkins, Clinical Cancer Research	2008	132
Heat-shock protein-25/27 phosphorylation by the δ isoform of protein kinase C Evelyn T. Maizels, Carl A. Peters, Michael Kline, Biochemical Journal	1998	116
Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Clinical Cancer Research	2018	109
An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, Cancer Discovery	2017	101
A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors Kyriakos P. Papadopoulos, Howard A. Burris, Michael S. Gordon, Cancer Chemotherapy and Pharmacology	2013	84
Stk10, a New Member of the Polo-like Kinase Kinase Family Highly Expressed in Hematopoietic Tissue Sarah A. Walter, Richard E. Cutler, Ricardo Martinez, Journal of Biological Chemistry Hematopoietic TissueStk10 TranscriptCell DeathTumor BiologySignaling Pathway	2003	72
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) Emiliano Cocco, F. Javier Carmona, Pedram Razavi, Science Signaling	2018	72
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i> Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Oncotarget	2017	63

Page 1